Literature DB >> 12719598

Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model.

Takahiro Niizuma1, Leigh Zerboni, Marvin H Sommer, Hideki Ito, Stewart Hinchliffe, Ann M Arvin.   

Abstract

We generated an ORF65 deletion mutant by using a cosmid system constructed from the genome of a low-passage clinical isolate (P-Oka). Using the SCID-hu mouse model, we demonstrated that the ORF65 protein is dispensable for viral replication in skin and T cells, which are critical host cell targets during primary varicella-zoster virus infection.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12719598      PMCID： PMC154042          DOI： 10.1128/jvi.77.10.6062-6065.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  16 in total

1.  Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking.

Authors:  S Mallory; M Sommer; A M Arvin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids.

Authors:  G Kemble; G Duke; R Winter; R Spaete
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

3.  Live vaccine used to prevent the spread of varicella in children in hospital.

Authors:  M Takahashi; T Otsuka; Y Okuno; Y Asano; T Yazaki
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  The 10K virion phosphoprotein encoded by gene US9 from herpes simplex virus type 1.

Authors:  M C Frame; D J McGeoch; F J Rixon; A C Orr; H S Marsden
Journal:  Virology       Date:  1986-04-30       Impact factor: 3.616

5.  Us9, a stable lysine-less herpes simplex virus 1 protein, is ubiquitinated before packaging into virions and associates with proteasomes.

Authors:  R Brandimarti; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

6.  The equine herpesvirus type 1 (EHV-1) homolog of herpes simplex virus type 1 US9 and the nature of a major deletion within the unique short segment of the EHV-1 KyA strain genome.

Authors:  C C Flowers; D J O'Callaghan
Journal:  Virology       Date:  1992-09       Impact factor: 3.616

7.  The complete DNA sequence and the genetic organization of the short unique region (US) of the bovine herpesvirus type 1 (ST strain).

Authors:  P Leung-Tack; J C Audonnet; M Riviere
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

8.  The DNA sequence of equine herpesvirus-1.

Authors:  E A Telford; M S Watson; K McBride; A J Davison
Journal:  Virology       Date:  1992-07       Impact factor: 3.616

9.  Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice.

Authors:  J F Moffat; M D Stein; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

10.  Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse.

Authors:  J F Moffat; L Zerboni; P R Kinchington; C Grose; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103
View more
  53 in total

1.  Identification and functional characterization of the Varicella zoster virus ORF11 gene product.

Authors:  Xibing Che; Stefan L Oliver; Marvin H Sommer; Jaya Rajamani; Mike Reichelt; Ann M Arvin
Journal:  Virology       Date:  2011-01-26       Impact factor: 3.616

2.  Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection.

Authors:  Barbara Berarducci; Minako Ikoma; Shaye Stamatis; Marvin Sommer; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo.

Authors:  Anne Schaap-Nutt; Marvin Sommer; Xibing Che; Leigh Zerboni; Ann M Arvin
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 4.  Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model.

Authors:  Chia-Chi Ku; Jaya Besser; Allison Abendroth; Charles Grose; Ann M Arvin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Mutational analysis of varicella-zoster virus (VZV) immediate early protein (IE62) subdomains and their importance in viral replication.

Authors:  Mohamed I Khalil; Xibing Che; Phillip Sung; Marvin H Sommer; John Hay; Ann M Arvin
Journal:  Virology       Date:  2016-02-23       Impact factor: 3.616

6.  Replication of varicella-zoster virus in human skin organ culture.

Authors:  Shannon L Taylor; Jennifer F Moffat
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

7.  Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Authors:  Heidi J Zapata; Masako Nakatsugawa; Jennifer F Moffat
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  ORF11 protein interacts with the ORF9 essential tegument protein in varicella-zoster virus infection.

Authors:  Xibing Che; Stefan L Oliver; Mike Reichelt; Marvin H Sommer; Jürgen Haas; Tihana L Roviš; Ann M Arvin
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

9.  Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection.

Authors:  Barbara Berarducci; Jaya Rajamani; Leigh Zerboni; Xibing Che; Marvin Sommer; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-04       Impact factor: 11.205

10.  Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors.

Authors:  Mohamed I Khalil; Marvin Sommer; Ann Arvin; John Hay; William T Ruyechan
Journal:  Virology       Date:  2013-03-21       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.